Could a Low-Dose start make opioid treatment easier?

NCT ID NCT05450718

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a low-dose method of starting buprenorphine-naloxone for opioid use disorder, compared to standard guidelines. The goal is to see if this approach is safe, effective, and acceptable to patients. The trial enrolls 70 adults with opioid use disorder who are willing to follow the assigned regimen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

buprenorphine-naloxone (low-dose initiation)

What this could lead to

If successful, this could make starting buprenorphine treatment easier and more comfortable for people with opioid use disorder, potentially increasing treatment uptake.

What could go wrong

This is a small pilot study with only 70 participants, focused on feasibility. It may not prove effectiveness, and low-dose initiation might not work for everyone or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-••••